Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 71 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Mantzoros, Christos S [Clear All Filters]
Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis..
Dig Dis Sci. 64(6), 1686-1694.
(2019). Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls..
Horm Metab Res. 51(2), 112-119.
(2019). Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?.
Metabolism. 96, iii-v.
(2019). Insulin resistance in relation to melanoma risk..
Melanoma Res. 21(6), 541-6.
(2011). Intracellular leptin signaling following effective weight loss..
Metabolism. 64(8), 888-95.
(2015). Irisin: a renaissance in metabolism?.
Metabolism. 62(8), 1037-44.
(2013). Irisin: A true, circulating hormone..
Metabolism. 64(12), 1611-8.
(2015). Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?.
Metabolism. 93, 100-102.
(2019). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Irisin in patients with nonalcoholic fatty liver disease..
Metabolism. 63(2), 207-17.
(2014). Juvenile Paget disease..
Metabolism. 80, 15-26.
(2018). Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives..
Cell Metab. 18(1), 29-42.
(2013). Leptin in health and disease: facts and expectations at its twentieth anniversary..
Metabolism. 64(1), 5-12.
(2015). Leptin in nonalcoholic fatty liver disease: a narrative review..
Metabolism. 64(1), 60-78.
(2015). Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals..
Endocr Rev. 34(3), 377-412.
(2013). Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications..
Metabolism. 72, A4-A10.
(2017). Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study..
Metabolism. 147, 155666.
(2023). Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?.
Metabolism. 121, 154796.
(2021). Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)..
Metabolism. 154318.
(2020). Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management..
Metabolism. 155936.
(2024). Metabolism, Clinical and Experimental: seventy years young and growing..
Metabolism. 155333.
(2022). Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need..
Curr Med Res Opin. 38(6), 885-888.
(2022). Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease..
Metabolism. 63(2), 161-7.
(2014). Nonalcoholic fatty future disease..
Metabolism. 65(8), 1007-16.
(2016).
(2019).